RxDoctor Payments Data

Rose Monardo, MD

Gynecology · Walnut Creek, CANPI 1407142250

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (44.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 77.8% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $2,266, more than ten times the $72 reported in 2019.

$5,736in general payments, 2019–2025

Across 79 payments — averaging $72.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • AbbVie$210
  • Hologic Sales And Service, LLC$159
  • Daiichi Sankyo Inc.$132
  • Biogen$127
  • Astellas Pharma US Inc$70
  • plus $576 from 17 others

What the payments were for

  • Travel & lodging$1,79231%
  • Food & beverage$1,40725%
  • Education$2,53744%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,736 in reported general payments places this provider in the 80th percentile of 247 gynecology providers in California.

See all gynecology providers in California

Medicare billing

Part B allowed, 2024
$38,144
Medicare patients
187
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol97$9,677
PremarinEstrogens, Conjugated13$6,280
YuvafemEstradiol21$3,183
Estradiol (Twice Weekly)Estradiol30$2,836
DottiEstradiol20$1,937
ProgesteroneProgesterone, Micronized24$686
Cephalexin14$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$37$6,28013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 gynecology providers in California.

Other gynecology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →